[1] http://www.unaids.org/en/dataanalysis.[2] M. Baba, H. Tanaka, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C.F. Perno, R.Walker, T.Miyasaka, Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative, Biochem. Biophys. Res. Commun. 165(1989) 1375-1381.[3] World Health Organization, J.U.N.P.o., UNICEF, Global HIV/AIDS response:Epidemic update and health sector progress towards universal access:Progress report 2011, World Health Organization, 2011.[4] T. Miyasaka, H. Tanaka, M. Baba, H. Hayakawa, R.T.Walker, J. Balzarini, E. De Clercq, A novel lead for specific anti-HIV-1 agents:1-[(2-Hydroxyethoxy) methyl]-6-(phenylthio)thymine, J. Med. Chem. 32(1989) 2507-2509.[5] C.M. Bailey, T.J. Sullivan, P. Iyidogan, J. Tirado-Rives, R. Chung, J. Ruiz-Caro, E. Mohamed, W. Jorgensen, R. Hunter, K.S. Anderson, Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase:Mechanism and proof-of-concept as a novel therapeutic design strategy, J. Med. Chem. 56(2013) 3959-3968.[6] K.M. Frey, D.E. Puleo, K.A. Spasov, M. Bollini, W.L. Jorgensen, K.S. Anderson, Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants, J. Med. Chem. 58(2015) 2737-2745.[7] L. He, P.C. Jurs, Assessing the reliability of a QSAR model's predictions, J. Mol. Graph. Model. 23(2005) 503-523.[8] A. Golbraikh, A. Tropsha, Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection, J. Comput. Aided Mol. Des. 16(2002) 357-369.[9] A. Golbraikh, A. Tropsha, Beware of q2! J. Mol. Graph. Model. 20(2002) 269-276.[10] A. Golbraikh, M. Shen, Z. Xiao, Y.-D. Xiao, K.-H. Lee, A. Tropsha, Rational selection of training and test sets for the development of validated QSAR models, J. Comput. Aided Mol. Des. 17(2003) 241-253.[11] S. Raic-Malic, D. Svedruzic, T. Gazivoda, A. Marunovic, A. Hergold-Brundic, A. Nagl, J. Balzarini, E. De Clercq,M.Mintas, Synthesis and antitumor activities of novel pyrimidine derivatives of 2,3-O,O-dibenzyl-6-deoxy-L-ascorbic acid and 4, 5-didehydro-5, 6-dideoxy-L-ascorbic acid, J. Med. Chem. 43(2000) 4806-4811.[12] L. Eriksson, J. Jaworska, A.P. Worth, M.T. Cronin, R.M. McDowell, P. Gramatica, Methods for reliability and uncertainty assessment and for applicability evaluations of classification-and regression-based QSARs, Environ. Health Perspect. 111(2003) 1361.[13] R. Garg, S.P. Gupta, H. Gao, M.S. Babu, A.K. Debnath, C. Hansch, Comparative quantitative structure-activity relationship studies on anti-HIV drugs, Chem. Rev. 99(1999) 3525-3602.[14] L. Douali, D. Villemin, D. Cherqaoui, Neural networks:Accurate nonlinear QSAR model for HEPT derivatives, J. Chem. Inf. Comput. Sci. 43(2003) 1200-1207.[15] V.P. Solov'ev, A. Varnek, Anti-HIV activity of HEPT, TIBO, and cyclic urea derivatives:Structure-property studies, focused combinatorial library generation, and hits selection using substructural molecular fragments method, J. Chem. Inf. Comput. Sci. 43(2003) 1703-1719.[16] Y. Akhlaghi, M. Kompany-Zareh, Application of radial basis function networks and successive projections algorithm in a QSAR study of anti-HIV activity for a large group of HEPT derivatives, J. Chemom. 20(2006) 1-12.[17] H. Bazoui, M. Zahouily, S. Boulajaaj, S. Sebti, D. Zakarya, QSAR for anti-HIV activity of HEPT derivatives, SAR QSAR Environ. Res. 13(2002) 567-577.[18] H.F. Chen, X.J. Yao, Q. Li, S.G. Yuan, A. Panaye, J.P. Doucet, B.T. Fan, Comparative study of non-nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking, SAR QSAR Environ. Res. 14(2003) 455-474.[19] W. Guo, X. Hu, N. Chu, C. Yin, Quantitative structure-activity relationship studies on HEPTs by supervised stochastic resonance, Bioorg. Med. Chem. Lett. 16(2006) 2855-2859.[20] Q. Wang, Q. Jia, L. Yan, S. Xia, P. Ma, Quantitative structure-toxicity relationship of the aquatic toxicity for various narcotic pollutants using the norm indexes, Chemosphere 108(2014) 383-387.[21] Z.C. Zhu, Q. Wang, Q.Z. Jia, S.Q. Xia, P.S. Ma, Structure-property relationship for the pharmacological and toxicological activity of heterocyclic compounds, Acta Phys. -Chim. Sin. 30(2014) 1086-1090.[22] Q. Jia, X. Cui, L. Li, Q.Wang, Y. Liu, S. Xia, P. Ma, A quantitative structure-activity relationship for high affinity 5-HT1A receptor ligands based on norm indexes, J. Phys. Chem. B 119(2015) 15561-15567.[23] H. Tanaka, H. Takashima, M. Ubasawa, K. Sekiya, I. Nitta, M. Baba, S. Shigeta, R.T. Walker, E. De Clercq, T. Miyasaka, Synthesis and antiviral activity of deoxy analogs of I-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents, J. Med. Chem. 35(1992) 4713-4719.[24] M. Baba, S. Shigeta, H. Tanaka, T. Miyasaka, M. Ubasawa, K. Umezu, R.T. Walker, R. Pauwels, E. De Clercq, Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives, Antivir. Res. 17(1992) 245-264.[25] (a) T. Miyasaka, H. Tanaka, M. Baba, H. Hayakawa, R.T. Walker, J. Balzarini, E. De Clercq, A novel lead for specific anti-HIV-1 agents:1-[(2-Hydroxyet hoxy) methyl]-6-(phenylthio)thymine, J. Med. Chem. 32(1989) 2507-2509;(b) M. Baba, H. Tanaka, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H.Nakashima, C.F. Perno, R.T.Walker, T. Miyasaka, Highly specific inhibition of human immunodeficiency firus type 1 by a novel substituted acyclouridine derivative, Biochem. Biophys. Res. Commun. 165(1989) 1375-1381;(c) M. Tanaka, M. Baba,M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, S. Shigeta, R.T. Walker, E. De Clercq, T.Miyasaka, Synthesis and anti-HIV activity of 2-,3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT), J. Med. Chem. 34(1991) 1394-1399;(d) H. Tanaka, M. Baba, S. Saito, T.Miyasaka, H. Takashima, K. Sekiya,M. Ubasawa, I. Nitta, R.T. Walker, H. Nakashima, E. De Clercq, Specific anti-HIV-1 "Acyclonucleosides" which cannot be phosphorylated:Synthesis of some deoxy analogues of 1-[(2-Hydroxyethoxy)methyll-6-(phenylthio)thymine, J. Med. Chem. 34(1991) 1508-1511;(e) H. Tanaka, M. Baba, H. Hayakawa, K. Haraguchi, T. Miyasaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, R.T. Walker, E. De Clercq, Lithiation of uracilnucleosides and its application to the synthesis of a new class of anti-HIV-1 acyclonucleosides, Nucleosides Nucleotides 10(1991) 397-400.[26] J.M. Luco, F.H. Ferretti, QSAR based on multiple linear regression and PLS methods for the anti-HIV activity of a large group of HEPT derivatives, J. Chem. Inf. Comput. Sci. 37(1997) 392-401.[27] Hyperchem.7.0. Hypercube, Inc., http://www.hyper.com 2001.[28] P. Gramatica, Principles of QSAR models validation:Internal and external, QSAR Comb. Sci. 26(2007) 694-701.[29] P. Gramatica, E. Giani, E. Papa, Statistical external validation and consensus modeling:A QSPR case study for Koc prediction, J. Mol. Graph. Model. 25(2007) 755-766.[30] H. Bazoui, M. Zahouily, S. Sebti, S. Boulajaaj, D. Zakarya, Structure-cytotoxicity relationships for a series of HEPT derivatives, J. Mol. Model. 8(2002) 1-7.[31] V.K. Agrawal, J. Singh, K.Mishra, P.V. Khadikar, QSAR study on cytotoxic activities of a series of HEPT analogues, Lett. Drug Des. Discovery 3(2006) 129-137.[32] C. Rücker, G. Rücker, M.Meringer, Y-randomization and its variants in QSPR/QSAR, J. Chem. Inf. Model. 47(2007) 2345-2357.[33] A. Tropsha, P. Gramatica, V.K. Gombar, The importance of being earnest:Validation is the absolute essential for successful application and interpretation of QSPR models, QSAR Comb. Sci. 22(2003) 69-77. |